← Evidence map

ArticleTherapeutics and clinical risk management2012

Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar).

Viroj WiwanitkitPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

28 papers cite it

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 22802694